← Back to patent-cliff list
Methylprednisolone aceponate (Tianjin Pharmaceutical Research Institute)
Tier C — Watch / tradeMethylprednisolone aceponate (Tianjin Pharmaceutical Research Institute)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Arachidonic acid
Indications (approved)：神经性皮炎, Eczema, Atopic dermatitis
Regional status
US
-
EU
-
China
Phase III
2013-10-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Methylprednisolone aceponate (Tianjin Pharmaceutical Research Institute)?
Approved indications include: 神经性皮炎, Eczema, Atopic dermatitis.
When does the Methylprednisolone aceponate (Tianjin Pharmaceutical Research Institute) patent expire?
No public expiry year is available for Methylprednisolone aceponate (Tianjin Pharmaceutical Research Institute) yet; this page updates once verified.
How do I get a quote for Methylprednisolone aceponate (Tianjin Pharmaceutical Research Institute) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-13